Additionally, a large RCT done in 342 COVID-19 patients with signs of cytokine release syndrome found that drugs targeting IL-1 (anakinra) or IL-6 (tocilizumab or siltuximab) did not shorten the time to clinical improvement [93]. The gene discussed is IL1A; the disease is COVID-19.